CRISPR and Cas Gene Market Report 2026

The crispr and cas gene market size has grown exponentially in recent years. It will grow from $4.81 billion in 2025 to $5.86 billion in 2026 at a compound annual growth rate (CAGR) of 21.8%. The growth in the historic period can be attributed to breakthrough discovery of crispr cas systems, reduced gene editing costs, academic research adoption, availability of research kits, government funding support.

The crispr and cas gene market size is expected to see exponential growth in the next few years. It will grow to $13.1 billion in 2030 at a compound annual growth rate (CAGR) of 22.3%. The growth in the forecast period can be attributed to clinical translation of gene editing, expansion of personalized medicine, growth of biotech startups, increasing research investments, advancements in delivery systems. Major trends in the forecast period include expansion of gene editing research applications, growing use in cell line engineering, increased adoption in drug discovery, development of advanced crispr libraries, growth of custom gene editing services.

The growing emphasis on personalized therapy is expected to drive the growth of the CRISPR and Cas gene market in the coming years. Personalized therapy refers to a medical approach that uses an individual’s genetic profile to guide decisions related to disease diagnosis, treatment, and prevention. CRISPR and Cas genes, particularly Cas9, play a key role in personalized medicine by enabling precise modifications to an individual’s genetic material, offering significant potential for the development of tailored therapies for genetic disorders, cancer, and other medical conditions. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based organization, the U.S. Food and Drug Administration approved 16 novel personalized therapies for rare disease patients in 2023, up from six approvals in 2022. Therefore, the increasing demand for personalized therapy is contributing to the growth of the CRISPR and Cas gene market.

Major companies operating in the CRISPR and Cas gene market are focused on developing innovative solutions such as CRISPR-based cell-based gene therapies to strengthen their product portfolios and gain competitive advantage. CRISPR-based cell-based gene therapy uses gene-editing technology to modify or correct genetic material within cells, providing a targeted and potentially transformative approach to treating genetic disorders, diseases, and other medical conditions at the cellular level. For example, in December 2023, Vertex Pharmaceuticals Incorporated, a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration for CASGEVY (exagamglogene autotemcel [exa-cel]). CASGEVY is a CRISPR/Cas9 genome-edited gene therapy for treating sickle cell disease in patients aged 12 years and older with recurrent vaso-occlusive crises. It is a first-of-its-kind therapy with the potential to serve as a one-time, transformative treatment for eligible patients. Administration of CASGEVY requires specialized training in stem cell transplantation, leading Vertex to collaborate with experienced institutions to establish a network of independently owned, approved treatment centers across the United States.

In July 2025, Eli Lilly and Company, a US-based pharmaceutical company, completed the acquisition of Verve Therapeutics, Inc. for an undisclosed amount. Through this acquisition, Lilly aims to advance one-time, CRISPR-based gene-editing therapies intended to provide long-term reduction in cardiovascular risk by integrating Verve’s in vivo gene-editing platforms into its cardiometabolic development pipeline. Verve Therapeutics, Inc. is a US-based clinical-stage biotechnology company focused on developing CRISPR-based gene-editing treatments for cardiovascular disease.

Major companies operating in the crispr and cas gene market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc, AstraZeneca plc, Danaher Corporation, Lonza Group AG, Bio-Rad Laboratories Inc., eGenesis, Novartis Institutes for BioMedical Research, GenScript, Takara Bio Inc., Merck KGaA, Horizon Discovery Group Plc, Beam Therapeutics Inc, Intellia Therapeutics Inc, New England BioLabs, Recursion Pharmaceuticals Inc, Caribou Biosciences Inc, Cellectis S.A., Editas Medicine Inc, CRISPR Therapeutics AG, Mammoth Biosciences, Inscripta Inc, Prime Medicine Inc, Precision BioSciences Inc, Sangamo Therapeutics Inc.

North America was the largest region in the CRISPR and Cas gene market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crispr and cas gene market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the crispr and cas gene market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the crispr and cas gene market by increasing costs of imported enzymes, reagents, laboratory instruments, and consumables. Biotechnology companies and research institutes in North America and Europe are most affected due to reliance on imported materials, while Asia-Pacific faces higher research input costs. These tariffs are increasing research expenses. However, they are also encouraging local reagent production and regional biotech ecosystem growth.

The crispr and cas gene market research report is one of a series of new reports that provides crispr and cas gene market statistics, including crispr and cas gene industry global market size, regional shares, competitors with a crispr and cas gene market share, detailed crispr and cas gene market segments, market trends and opportunities, and any further data you may need to thrive in the crispr and cas gene industry. This crispr and cas gene market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, along with Cas (CRISPR-associated) genes, particularly Cas9, form an advanced gene-editing technology. This system allows highly accurate modifications of DNA sequences and has transformed genetic research, biotechnology, and potential medical applications.

The primary product types in the CRISPR and Cas gene market include kits and enzymes, libraries, design tools, antibodies, and other products. Kits and enzymes are fundamental components of CRISPR-based gene editing, with kits providing the necessary reagents and tools for research activities, while enzymes such as Cas9 play a critical role in executing the gene-editing process. The associated services are categorized into cell line engineering, gRNA design, microbial gene editing, and DNA synthesis. These services are applied across clinical, financial, operational, and administrative functions and are utilized by end users including biotechnology and pharmaceutical companies, academic and government research institutions, and contract research organizations (CROs).

The CRISPR and Cas gene market consists of revenues earned by entities by offering services such as gene editing, targeted disruption of genes, targeted drug development, livestock breeding, and animal model construction. The market value includes the value of related goods sold by the service provider or included within the service offering. The CRISPR and Cas gene market also includes sales of RNA clean-up kits, phenol-free kits, t7 polymerase mix, and RNAse-free water. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.